RDY (Dr. Reddy's Laboratories) Expected net earnings per share growth this year

Dr. Reddy's Laboratories (RDY), an Indian leader in the API and generics segment, is growing through biosimilars and R&D. The company minimizes risks by supplying hundreds of drugs to global pharmacy chains. Its technological stack is complemented by robotic packaging lines and digital compliance. The value of -15.50 determines the current parameter status; by verifying the year-over-year EPS change on GURU.Markets, we can see the earnings per share dynamics.
Analytical breakdowns and data insights for company Dr. Reddy's (RDY)

The implementation of green chemistry methods and strict ESG controls at Dr. Reddy's Laboratories (RDY) plants require significant capital expenditures for wastewater treatment. The year-over-year EPS dynamics reflect the efficiency of managing these costs relative to revenue, measuring the growth rate of net profit per share; peak values confirm high margins, however, purchasing the asset at highs carries the risk of capital freeze.